96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D048588:Benzoxazines / Q000008:administration & dosage / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D018791:CD4 Lymphocyte Count; D003510:Cyclohexanes / Q000008:administration & dosage / Q000627:therapeutic use; D003521:Cyclopropanes; D004311:Double-Blind Method; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use; D000077592:Maraviroc; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D003521:Cyclopropanes; D004338:Drug Combinations; D023581:HIV Fusion Inhibitors; D018894:Reverse Transcriptase Inhibitors; D014230:Triazoles; C109078:lamivudine, zidovudine drug combination; D019259:Lamivudine; D015215:Zidovudine; C098320:efavirenz; D000077592:Maraviroc